Inventor · disambiguated record
Kenneth M. Attie
Also filed as: ATTIE KENNETH · ATTIE KENNETH M
12 granted patents·8 pending applications·243 citations·filing 1990–2022
92Inventor score
Top patents by PatentIndex Score
20 records- 0197US10487144B2Methods for treating ulcers in a hemoglobinopathy anemia with a soluble actRIIB polypeptideACCELERON PHARMA INC·Filed 2017·Granted Nov 26, 2019·16 cites·21 claims
- 0297US9850298B2Methods for treating ulcers in thalassemia syndrome with an ActRIIB polypeptideACCELERON PHARMA INC·Filed 2015·Granted Dec 26, 2017·23 cites·26 claims
- 0396US10550170B2Methods for treating vascular eye disorders with actrii antagonistsACCELERON PHARMA INC·Filed 2016·Granted Feb 4, 2020·21 cites·44 claims
- 0494US10189882B2Methods for treating myelodysplastic syndromes and sideroblastic anemiasACCELERON PHARMA INC·Filed 2015·Granted Jan 29, 2019·21 cites·25 claims
- 0589US5646113ATreatment of partial growth hormone insensitivity syndromeGENENTECH INC·Filed 1994·Granted Jul 8, 1997·81 cites·8 claims
- 0687US11524990B2Methods for treating vascular eye disorders with ActRII antagonistsACCELERON PHARMA INC·Filed 2019·Granted Dec 13, 2022·2 cites·43 claims
- 0783US11260107B2Methods and compositions for treating ulcersACCELERON PHARMA INC·Filed 2019·Granted Mar 1, 2022·1 cites·21 claims
- 0875US5824642ATreatment of partial growth hormone insensitivity syndromeGENENTECH INC·Filed 1995·Granted Oct 20, 1998·28 cites·16 claims
- 0975US5166190AMethod for increasing fertility in malesGENENTECH INC·Filed 1990·Granted Nov 24, 1992·47 cites·8 claims
- 1074US2022133853A1Methods and compositions for treating ulcersACCELERON PHARMA INC·Filed 2021·Application pending·0 cites
- 1173US11471510B2Activin-ActRII antagonists and uses for treating anemiaCELGENE CORP·Filed 2015·Granted Oct 18, 2022·2 cites·20 claims
- 1269US10829531B2Methods for treating myelodysplastic syndromes and sideroblastic anemiasACCELERON PHARMA INC·Filed 2018·Granted Nov 10, 2020·0 cites·29 claims
- 1365US2021115105A1Actriib antagonists and dosing and uses thereofACCELERON PHARMA INC·Filed 2020·Application pending·0 cites
- 1465US2021230239A1Methods for treating myelodysplastic syndromes and sideroblastic anemiasACCELERON PHARMA INC·Filed 2020·Application pending·0 cites
- 1555US2018194828A1Actriib antagonists and dosing and uses thereofACCELERON PHARMA INC·Filed 2017·Application pending·0 cites
- 1654US2023142386A1Activin-actrii antagonists and uses for treating anemiaCELGENE CORP·Filed 2022·Application pending·0 cites
- 1750US2011070233A1Actriib antagonists and dosing and uses thereofACCELERON PHARMA INC·Filed 2010·Application pending·0 cites
- 1842US2021346464A1TREATMENT OF ANEMIA DUE TO VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES IN SUBJECTS WITH RING SIDEROBLASTS USING ACTIVIN-ACTRll LIGAND TRAPSCELGENE CORP·Filed 2019·Application pending·0 cites
- 1938US2018125928A1Treatment of beta-thalassemia using actrii ligand trapsCELGENE CORP·Filed 2016·Application pending·0 cites
- 2032US6207640B1Treatment of partial growth hormone insensitivity syndromeGENENTECH INC·Filed 1996·Granted Mar 27, 2001·1 cites·21 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →